Going for broke, Tricida is slamming the brakes on a pivotal trial early while planning a run at the FDA
Two years after a bitter setback at the FDA, with its cash reserves ebbing away, Tricida is executing a high-stakes gamble on winning a swift approval at the FDA. A win would put them back in play with a new drug to commercialize. A loss, as one Wall Street analyst recently assessed, would take the stock to zero.
Today Tricida $TCDA announced an “administrative stop” for its VALOR-CKD trial after watching 237 patients reach a primary endpoint event — renal death, end-stage renal disease, or greater than or equal to 40% reduction in estimated glomerular filtration rate — in the renal outcomes study for their metabolic acidosis and CKD drug veverimer. They’ll continue to track events into Q3 as they look for a top-line readout in the near term.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.